Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
458 active trials5 approved drugs36 evidence items
- NCIt
- C181162
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Clinical trials
1,481 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05737199 | Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma | active not recruiting | Phase 2 | 21 | Niigata University Medical & Dental HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06804135 | Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer(STIRR) | recruiting | — | 110 | Tata Memorial HospitalOTHER_GOV | 1 | Feb 4, 2026 |
| clinicaltrials |
| NCT03296826 | Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 | recruiting | — | 600 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06469281 | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers | recruiting | Phase 1 | 90 | Regeneron PharmaceuticalsINDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07280312 | Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions | recruiting | N/A | 40 | Mayo ClinicOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06639191 | [177Lu]Lu-AKIR001 First-in-human Study(AKIR001) | recruiting | Early Phase 1 | 15 | Karolinska University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07378371 | Proactive Temperature Management in CRS-HIPEC for Prevention of Delirium | not yet recruiting | N/A | 174 | Aerospace Center HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05542407 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | recruiting | Phase 1 | 58 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07374809 | IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER(DEMETER) | not yet recruiting | N/A | 50 | European Institute of OncologyOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05129969 | Registry Platform Ovarian and Endometrial Cancer(SMARAGD) | recruiting | — | 1,975 | iOMEDICO AGINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07368985 | Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer | not yet recruiting | Phase 2 | 87 | Prof. Dr. Remi A. NoutOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04576104 | Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer | active not recruiting | Phase 2 | 51 | Northwestern UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04024917 | Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis(COCOON) | recruiting | N/A | 60 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07343531 | A Study Of Moderately Hypo-Fractionated External-beam Radiotherapy With Concurrent Chemotherapy and High Dose Rate Brachytherapy In Cervical Cancer | recruiting | N/A | 30 | Ain Shams UniversityOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07341360 | Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei(Pseudovax) | recruiting | Early Phase 1 | 10 | Oslo University HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06238635 | Dostarlimab and Cobolimab in Advanced Cervical Cancer | active not recruiting | Phase 2 | 66 | Meghan SheaOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07328737 | One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei | recruiting | N/A | 132 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04204811 | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy | active not recruiting | N/A | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05504252 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2) | active not recruiting | Phase 2 | 80 | University Hospital, AkershusOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06518564 | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer | recruiting | Phase 2 | 25 | Panagiotis Konstantinopoulos, MD, PhDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07305727 | A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer(EPICOL-R) | recruiting | — | 120 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07316361 | GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer(GYNORYLAQ™) | enrolling by invitation | Early Phase 1 | 40 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06666192 | The Ohio State University (OSU) SCREEN Community Program | recruiting | N/A | 2,067 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT04670068 | Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian | active not recruiting | Phase 1 | 4 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05407025 | Targeting Inflammation for Endometrial Cancer Prevention | active not recruiting | — | 191 | Mayo ClinicOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07295132 | RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) | not yet recruiting | Phase 2 | 160 | Asan Medical CenterOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT07030907 | A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer | recruiting | Phase 1 | 30 | Outpace Bio, Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients(RAMP201J) | active not recruiting | Phase 2 | 16 | Verastem, Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03422198 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer(SAVE) | recruiting | Phase 3 | 188 | University of UtahOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT06611072 | OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study(RENAISSANCE) | recruiting | N/A | 90 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT07269574 | Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance | not yet recruiting | — | 600 | Tongji HospitalOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07267780 | Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases. | not yet recruiting | — | 130 | National Cancer Institute, NaplesOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07268469 | Minimal Residual Disease in Solid Malignancies(IMRD) | not yet recruiting | N/A | 840 | European Institute of OncologyOTHER | 0 | Dec 5, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT07057167 | Prediction of Ovarian Cancer Histotypes and Surgical Outcome(PANtHer-AI) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Nov 20, 2025 | clinicaltrials |
| NCT05236686 | Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer | recruiting | N/A | 94 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Nov 19, 2025 | clinicaltrials |
| NCT03954171 | Platino-resistance in Ovarian Cancer(PlatinOv) | recruiting | N/A | 600 | Institut Claudius RegaudOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05773859 | NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer(NEODOC) | recruiting | Phase 1 / Phase 2 | 10 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05984875 | The Immune Landscape of Epithelial Ovarian Cancer(IOSI-GYNE-001) | recruiting | — | 74 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05997017 | Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | recruiting | Phase 2 | 29 | Aadi Bioscience, Inc.INDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT01230346 | Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer | active not recruiting | N/A | 493 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 5, 2026source: clinicaltrials